OncoMatch/Clinical Trials/NCT06874946
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
Is NCT06874946 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies CD5-targeted CAR-T cells for precursor t-cell lymphoblastic leukemia-lymphoma.
Treatment: CD5-targeted CAR-T cells — To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 expression (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
Serum creatinine clearance ≥60 mL/min (Cockcroft-Gault formula) or creatinine ≤1.5× ULN
Liver function
AST and ALT ≤5× upper limit of normal (ULN); total bilirubin ≤2× ULN
Cardiac function
QTc interval <480 ms (Fridericia correction formula); NYHA Class I heart failure or better; LVEF ≥50%; no unstable angina or acute MI within 6 months; no poorly controlled hypertension; no clinically significant arrhythmias
Adequate major organ function, defined as: AST and ALT ≤5× ULN; total bilirubin ≤2× ULN; Serum creatinine clearance ≥60 mL/min or creatinine ≤1.5× ULN. Clinically significant cardiovascular diseases, including any of the following: QTc interval ≥480 ms (Fridericia correction formula), NYHA Class II or higher heart failure, unstable angina or acute myocardial infarction within 6 months prior to signing the ICF, LVEF <50%, poorly controlled hypertension, clinically significant arrhythmias or those requiring antiarrhythmic treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06874946 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD5?
Yes, CD5 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify